Literature DB >> 33007437

A new understanding of GHSR1a--independent of ghrelin activation.

Xue Xiao1, Mingxia Bi1, Qian Jiao1, Xi Chen1, Xixun Du2, Hong Jiang3.   

Abstract

Growth hormone secretagogue receptor 1a (GHSR1a), a member of the G protein-coupled receptor (GPCR) family, is a functional receptor of ghrelin. The expression levels and activities of GHSR1a are affected by various factors. In past years, it has been found that the ghrelin-GHSR1a system can perform biological functions such as anti-inflammation, anti-apoptosis, and anti-oxidative stress. In addition to mediating the effect of ghrelin, GHSR1a also has abnormally high constitutive activity; that is, it can still transmit intracellular signals without activation of the ghrelin ligand. This constitutive activity affects brain functions, growth and development of the body; therefore, it has profound impacts on neurodegenerative diseases and some other age-related diseases. In addition, GHSR1a can also form homodimers or heterodimers with other GPCRs, affecting the release of neurotransmitters, appetite regulation, cell proliferation and insulin release. Therefore, further understanding of the constitutive activities and dimerization of GHSR1a will enable us to better clarify the characteristics of GHSR1a and provide more therapeutic targets for drug development. Here, we focus on the roles of GHSR1a in various biological functions and provide a comprehensive summary of the current research on GHSR1a to provide broader therapeutic prospects for age-related disease treatment.
Copyright © 2020 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Constitutive activity; GHSR1a; GPCR; Heterodimers

Mesh:

Substances:

Year:  2020        PMID: 33007437     DOI: 10.1016/j.arr.2020.101187

Source DB:  PubMed          Journal:  Ageing Res Rev        ISSN: 1568-1637            Impact factor:   10.895


  6 in total

Review 1.  "Sibling" battle or harmony: crosstalk between nesfatin-1 and ghrelin.

Authors:  Xi Chen; Jing Dong; Qian Jiao; Xixun Du; Mingxia Bi; Hong Jiang
Journal:  Cell Mol Life Sci       Date:  2022-03-03       Impact factor: 9.261

Review 2.  LEAP-2: An Emerging Endogenous Ghrelin Receptor Antagonist in the Pathophysiology of Obesity.

Authors:  Xuehan Lu; Lili Huang; Zhengxiang Huang; Dandan Feng; Richard J Clark; Chen Chen
Journal:  Front Endocrinol (Lausanne)       Date:  2021-08-24       Impact factor: 5.555

Review 3.  Advances in the Development of Nonpeptide Small Molecules Targeting Ghrelin Receptor.

Authors:  Gianfabio Giorgioni; Fabio Del Bello; Wilma Quaglia; Luca Botticelli; Carlo Cifani; E Micioni Di Bonaventura; M V Micioni Di Bonaventura; Alessandro Piergentili
Journal:  J Med Chem       Date:  2022-02-14       Impact factor: 7.446

4.  Serum levels of ghrelin and LEAP2 in patients with type 2 diabetes mellitus: correlation with circulating glucose and lipids.

Authors:  Jiaxi Li; Pu Huang; Jing Xiong; Xinyue Liang; Mei Li; Hao Ke; Chunli Chen; Yang Han; Yanhong Huang; Yan Zhou; Ziqiang Luo; Dandan Feng; Chen Chen
Journal:  Endocr Connect       Date:  2022-05-27       Impact factor: 3.221

Review 5.  Targeting the Ghrelin Receptor as a Novel Therapeutic Option for Epilepsy.

Authors:  An Buckinx; Dimitri De Bundel; Ron Kooijman; Ilse Smolders
Journal:  Biomedicines       Date:  2021-12-27

6.  Ghrelin attenuates drowning injury via dual effects on damage protection and immune repression.

Authors:  Min Chen; Hongwei Lin; Yanjun Gao; Zaiqiang Wang; Yujuan Li; Faguang Jin
Journal:  Ann Transl Med       Date:  2021-06
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.